Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT6A | Q92794 | 4/20 | 0.58 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.55 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.55 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.55 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.54 |
| ▸ | HTR2C | P28335 | 1/20 | 0.53 |
| ▸ | NAMPT | P43490 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31180472 | 1.00 | KAT6A (0.58) | KAT6ATAS1R3TAS1R1TAS1R2GPR139 | |
| Hydrochloric Acid SCHEMBL30978290 | 0.98 | KAT6A (0.56) | KAT6ATAS1R3TAS1R1TAS1R2GPR139 | |
| SCHEMBL7238448 | 0.86 | MAPT (0.55) | KAT6ATAS1R3TAS1R1TAS1R2GPR139 | |
| SCHEMBL14881985 | 0.85 | HDAC8 (0.64) | KAT6ATAS1R3TAS1R1TAS1R2GPR139 | |
| SCHEMBL30184372 | 0.84 | TAS1R3 (0.56) | KAT6ATAS1R3TAS1R1TAS1R2GPR139 | |
| SCHEMBL27971451 | 0.84 | KAT6A (0.58) | KAT6ATAS1R3TAS1R1TAS1R2GPR139 | |
| SCHEMBL18525797 | 0.84 | TAS1R3 (0.59) | KAT6ATAS1R3TAS1R1TAS1R2GPR139 | |
| SCHEMBL30870756 | 0.84 | TAS1R3 (0.59) | KAT6ATAS1R3TAS1R1TAS1R2GPR139 | |
| SCHEMBL14528870 | 0.84 | GPR139 (0.61) | KAT6ATAS1R3TAS1R1TAS1R2GPR139 | |
| SCHEMBL15901856 | 0.83 | KAT6A (0.61) | KAT6ATAS1R3TAS1R1TAS1R2GPR139 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1392219-A4 | SUBSTITUTED N'-(ARYLCARBONYL)-BENZHYDRAZIDES, N'-(ARYLCARBONYL)-BENZYLIDENE-HYDRAZIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOTOSIS AND THE USE THEREOF | CYTOVIA INC (US) | 2007-01-24 | — | — | EP | claimed |
| US-20040186078-A1 | Substituted N'-(arylcarbonyl)-benzhydrazides, N'-(arylcarbonyl)-benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2004-09-23 | — | — | US | claimed |
| US-6716859-B2 | ANTICANCER AGENTS | CYTOVIA, INC. | 2004-04-06 | — | — | US | claimed |
| EP-1392219-A2 | SUBSTITUTED N'-(ARYLCARBONYL)-BENZHYDRAZIDES, N'-(ARYLCARBONYL)-BENZYLIDENE-HYDRAZIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOTOSIS AND THE USE THEREOF | Cytovia, Inc. (US) | 2004-03-03 | — | — | EP | claimed |
| US-20030013743-A1 | Substituted N'-(arylcarbonyl)-benzhydrazides, N'-(arylcarbonyl)-benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2003-01-16 | — | — | US | claimed |
| WO-2002089745-A2 | SUBSTITUTED N'-(ARYLCARBONYL)-BENZHYDRAZIDES, N'-(ARYLCARBONYL)-BENZYLIDENE-HYDRAZIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2002-11-14 | — | — | WO | claimed |
| EP-4441052-B1 | COMPOUNDS | FUNDACION DEL SECTOR PUBLICO ESTATAL CENTRO NAC DE INVESTIGACIONES ONCOLOGICAS CARLOS III F S P CNIO (ES) | 2025-11-19 | — | — | EP | disclosed |
| US-20250042918-A1 | COMPOUNDS | Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P.CNIO) (ES) | 2025-02-06 | — | — | US | disclosed |
| EP-4441052-A1 | COMPOUNDS | Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) (ES) | 2024-10-09 | — | — | EP | disclosed |
| CN-118401527-A | Compounds of formula (I) | 国家公共部门基金会卡洛斯三世国家癌症研究中心(F.S.P.CNIO) | 2024-07-26 | — | — | CN | disclosed |
| WO-2023099072-A1 | COMPOUNDS | Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) (ES) | 2023-06-08 | — | — | WO | disclosed |
| WO-2023097386-A1 | SELECTIVE HDAC6-INHIBITING N-ACYLHYDRAZONE COMPOUNDS, METHODS FOR PRODUCING SAME, COMPOSITIONS, USES, TREATMENT METHODS AND KITS | EUROFARMA LABORATÓRIOS S.A (BR) | 2023-06-08 | — | — | WO | disclosed |
| WO-2023097386-A1 | SELECTIVE HDAC6-INHIBITING N-ACYLHYDRAZONE COMPOUNDS, METHODS FOR PRODUCING SAME, COMPOSITIONS, USES, TREATMENT METHODS AND KITS | EUROFARMA LABORATÓRIOS S.A (BR) | 2023-06-08 | — | — | WO | disclosed |
| EP-1392219-A2 | SUBSTITUTED N'-(ARYLCARBONYL)-BENZHYDRAZIDES, N'-(ARYLCARBONYL)-BENZYLIDENE-HYDRAZIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOTOSIS AND THE USE THEREOF | Cytovia, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| EP-1070708-B1 | Triazole derivatives | HOFFMANN LA ROCHE (CH) | 2004-01-14 | — | — | EP | disclosed |
| US-20030013743-A1 | Substituted N'-(arylcarbonyl)-benzhydrazides, N'-(arylcarbonyl)-benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2003-01-16 | — | — | US | disclosed |
| WO-2002089745-A2 | SUBSTITUTED N'-(ARYLCARBONYL)-BENZHYDRAZIDES, N'-(ARYLCARBONYL)-BENZYLIDENE-HYDRAZIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2002-11-14 | — | — | WO | disclosed |
| US-6265426-B1 | CENTRAL NERVOUS SYSTEM DISORDERS | HOFFMANN-LA ROCHE INC. | 2001-07-24 | — | — | US | disclosed |
| CN-1281852-A | Triazole and imidazole derivative | HOFFMANN LA ROCHE (CH) | 2001-01-31 | — | — | CN | disclosed |
| EP-1070708-A1 | Triazole and imidazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2001-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186078-A1 | Substituted N'-(arylcarbonyl)-benzhydrazides, N'-(arylcarbonyl)-benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP2, CASP1, BCL2 | KAT6A 1646/4885TAS1R3 2096/4885TAS1R1 1094/4885 |
| US-20030013743-A1 | Substituted N'-(arylcarbonyl)-benzhydrazides, N'-(arylcarbonyl)-benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP2, CASP1, BCL2 | KAT6A 1646/4885TAS1R3 2096/4885TAS1R1 1094/4885 |
| US-20250042918-A1 | COMPOUNDS | PIM1, PIM3, PIM2 | KAT6A 843/4885TAS1R3 1820/4885TAS1R1 1960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.